Anti-idiotype monoclonal antibody in the diagnosis and trectment of non-small cell carcinoma of the long

抗独特型单克隆抗体在长发非小细胞癌诊断和治疗中的应用

• 批准号: 02454324
• 负责人: FUJISAWA Takehiko
• 金额: $ 4.29万
• 依托单位: Chiba University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (B)
• 财政年份: 1990
• 资助国家: 日本
• 起止时间: 1990 至 1992
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-02454324/
• 关键词: anti-idiotype antibody; hybridoma; cellmediated immunit; delayed type cutaneous hypersoustivity veactions; 細胞融合法; 遅延型皮膚反応; 免疫賦活剤; モノクロ-ナル抗体; 肺癌; 免疫療法; 免疫賦汚; 外科療法; 合併療法

The objective of this study was to improve the diagnosis and treatment f or lung cancer patients by producing anti-idiotype monoclonal antibody against antigen binding site of 4G12 monoclonal antibody with human type IgM and highly reaction to lung carcinomas. The results obtained were as follows:1)Four cell lines producing anti-idiotype monoclonal antibody(IgG1)(2H1, 2B12,2E10,7A8) spacifically reacted with 4G12 antibody and not reacted with human IgM,human IgG,normal human serum and another human type monoclonal antibody to small cell carcinomas.2)Inhibition assay using 3 monoclonal antibodies(2B12,2E10,7A8) demonstrated approximately 90% inhibition of reaction between ^<125>I labelled 4G12 and established squamous cell carcinoma line PC-10,thus indicating these 3 monoclonal antibodies Ab2beta.3)Preoperative delayed type cutaneous hypersensitivity reactions to PPD, candida and SK/SD demonstrated the decrease of the positiveness in parallel with age,and SK/SD reaction showed statistically specific difference between the result of age 69 years old or below and 70 years old or more,in particular.4)Postoperative respiratory complications occurred significantly highly in patients with SK/SD negative reaction in comparison with in those with SK/S D positive reaction,demonstrating the usefulness of SK/SD reaction as a immune parameter for prediction of postoperative respiratory complications and the significance of enhancement of SK/SD cutaneous reaction at preoperative stage for the inhibition of resparatory complications.

本研究的目的是通过生产针对人型IgM的4G12单克隆抗体的抗原结合位点且对肺癌高度反应的抗独特型单克隆抗体，以改善肺癌患者的诊断和治疗。所得结果如下：1)产生抗独特型单克隆抗体(IgG1)(2H1、2B12、2E10、7A8)的4个细胞系与4G12抗体特异性反应，与人IgM、人IgG、正常人血清和另一种抗小细胞癌的人型单克隆抗体不反应。2)用3种细胞进行抑制实验。 单克隆抗体（2B12，2E10，7A8）显示出对^<125>I标记的4G12和已建立的鳞状细胞癌细胞系PC-10之间的反应有约90％的抑制，从而表明这3种单克隆抗体Ab2beta。3）术前对PPD，念珠菌和SK/SD的迟发型皮肤超敏反应显示 4）SK/SD阴性反应患者与SK/SD阳性反应患者相比，SK/SD反应阳性患者术后呼吸系统并发症发生率显着升高，证明SK/SD反应作为免疫参数预测术后呼吸系统并发症的有用性。 术前增强SK/SD皮肤反应对于抑制修复并发症的意义。

项目成果

斎藤 幸雄: "自然退縮したと考えられるIV期肺癌の1例" 日本胸部疾患学会雑誌. 29. 95-100 (1991)

Yukio Saito：“一例似乎已自发消退的 IV 期肺癌”日本胸科疾病学会杂志 29. 95-100 (1991)。

Masayuki Baba,Yutaka Yamaguchi,Takehiko Fujisawa: "Recent Advances in Transfer Factor and heucocyte Extracts" Takehiko Fujisawa,Yutaka Yamaguchi, 500 (1991)

Masayuki Baba、Yutaka Yamaguchi、Takehiko Fujisawa：“转移因子和白细胞提取物的最新进展” Takehiko Fujisawa、Yutaka Yamaguchi，500（1991）

Takehiko Fujisawa: "Biological nature of cancers,squamous cell carcinoma and adenocarcinoma" GEKACHIRYOU(SURG TREAT). 63-5. 522-526 (1990)

Takehiko Fujisawa：“癌症、鳞状细胞癌和腺癌的生物学性质”GEKACHIRYOU（SURG TREAT）。

藤沢 武彦 他: "老年者肺癌の特異性と対策ー特に外科治療の進歩と限界" 日本胸部疾患学会雑誌. (1992)

Takehiko Fujisawa 等人：“老年肺癌的特点和对策 - 特别是手术治疗的进展和局限性”日本胸科疾病学会杂志（1992 年）。

藤沢 武彦: "原発性肺癌切除例に対する術後補助療法" 日本外科系連合学会誌. 14. 70-73 (1990)

Takehiko Fujisawa：“原发性肺癌切除病例的术后辅助治疗”日本外科联合会杂志 14. 70-73 (1990)。